Q-omics provides the consensus-scored KCTD8 profile across patient tissues and cancer cell-line models. KCTD8 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KCTD8 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, KCTD8 protein abundance shows 13,697 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where KCTD8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCTD8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCTD8 survival associations across molecular data types. KCTD8 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCTD8 RNA expression–survival associations across cancer types. High KCTD8 expression shows unfavorable associations in UVM, SCLC and LIHC, but favorable associations in ACC, PAAD and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for KCTD8 RNA expression.
This table summarizes KCTD8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KCTD8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCTD8 shows lower tumor expression in KIRC, THCA, HNSC, STAD, UCEC and BRCA. The KIRC box plot shows higher KCTD8 RNA expression in normal versus tumor tissue (log2 FC = −1.211, t-test p < 0.001).
This table shows molecular features associated with KCTD8 in patient tissues and cancer cell lines. In patient samples, KCTD8 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KCTD8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
